Fig. 2From: Neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: a real-world retrospective single-institutional study in ChinaForest plot of factors associated with pCRBack to article page